Navigation Links
NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
Date:9/21/2007

bsequent 12-week study period.

Anthony A. DiTonno, President and CEO, commented, "I am very pleased with our ability to complete the enrollment of this study ahead of plan. When we completed our initial public offering earlier this year, we indicated that we would file a new drug application (NDA) with the Food and Drug Administration (FDA) in the second half of 2008. Completion of enrollment in this study, on top of our three already completed successful Phase 3 trials, increases our confidence that we can meet this goal."

NeurogesX has successfully completed two Phase 3 studies in postherpetic neuralgia (PHN) and one in HIV-DSP. NGX-4010 has been granted orphan status and has received fast track designation from the FDA for HIV-DSP. NeurogesX believes that it is on track to file for marketing approval in the European Union before the end of 2007 for a broad indication of peripheral neuropathic pain. The Company is currently evaluating various regulatory filing strategies in the United States in order to most efficiently seek FDA approval of both the PHN and HIV-DSP indications, and believes that it will be able to submit a new drug application with the FDA in 2008.

About PHN and HIV-DSP

PHN is a painful condition affecting sensory nerve fibers. It is a complication of shingles, a second outbreak of the varicella-zoster virus, which initially causes chickenpox. Following an initial infection, some of the virus can remain dormant in nerve cells. Years later, age, illness, stress, medications or other factors that are not well understood can lead to reactivation of the virus. The rash and blisters associated with shingles usually heal within six weeks, but some people continue to experience pain for years thereafter. This pain is known as postherpetic neuralgia. PHN may occur in almost any area, but is especially common on the torso.

HIV-DSP is caused primarily by three factors: direct activation of cells known as sensory neurons by the
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
2. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
3. Celsion Completes Enrollment in Phase I Liver Cancer Study
4. LANI completes Phase I in Japan and to commence Phase I in UK
5. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
8. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014 Actavis plc (NYSE: ... Food and Drug Administration (FDA) has accepted for filing ... drug for the treatment of diarrhea and abdominal pain ... Syndrome (IBS-D).  Actavis, NDA for eluxadoline has been granted ... http://photos.prnewswire.com/prnh/20130124/NY47381LOGO "The NDA filing ...
(Date:9/2/2014)... 2, 2014 ResMed (NYSE: RMD ) ... in the United States . The ... and user-friendly life support ventilators. ResMed,s ... ease of use for patients suffering from neuromuscular disease, ... childhood respiratory disorders. The U.S. launch comes on the ...
(Date:9/2/2014)... 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... Administration (FDA) has granted orphan drug status to APD811 ... "The FDA Office of Orphan Products Development (OOPD) ... identify and designate drug candidates that could potentially treat ... of such products," said Craig M. Audet , ...
Breaking Medicine Technology:Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 2Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 3Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 4ResMed's Revolutionary Life Support Ventilation Platform -- Astral 100 and 150 Devices Now Available in the U.S. 2ResMed's Revolutionary Life Support Ventilation Platform -- Astral 100 and 150 Devices Now Available in the U.S. 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 4
... The TandemHeart circulatory support system has been granted ... Contractor (MAC) serving over 1.3 million beneficiaries and over ... United States. "We are extremely pleased with ... TandemHeart system," said  Kraig McEwen, President and CEO of ...
... ELGX ), developer and marketer of minimally invasive ... release of its second quarter 2011 financial results, which will ... of the market. Endologix will hold a conference ... / 2:00 p.m. PT to discuss the results. The dial-in ...
Cached Medicine Technology:TandemHeart Approved for Expanded Reimbursement 2Endologix to Report Second Quarter 2011 Financial Results on July 21, 2011 2
(Date:9/2/2014)... News) -- The quality of Americans, diets has improved ... the rich and poor is growing, a new study ... to date that the extensive efforts by many groups ... some payoff, but it also indicates that these efforts ... doctoral student in the department of nutrition at the ...
(Date:9/2/2014)... Amy Norton HealthDay Reporter , ... want to lose weight and boost their heart health, cutting ... a new study suggests. In a small clinical trial ... a low-carbohydrate diet lost more weight over a year than ... bigger improvements in their cholesterol and triglyceride levels, the research ...
(Date:9/2/2014)... Philadelphia, PA (PRWEB) September 02, 2014 ... Magee Rehabilitation Hospital returns on September 19 at The ... Hill, Pennsylvania. Over the past 25 years, the Classic, ... more than $12 million for programs and services designed ... at Magee Rehabilitation Hospital. , “The Segal Classic ...
(Date:9/2/2014)... 02, 2014 North America Resectoscopes ... Market Outlook to 2020? provides key market data ... provides value, in millions of US dollars, volume ... within market segments –,     Rigid ... Reusable) Electrodes and Bipolar (Disposable and Reusable) Electrodes). ...
(Date:9/2/2014)... 02, 2014 Humility of Mary Health Partners ... at St. Elizabeth Health Center, 1044 Belmont Ave. , The ... more than 200 common health problems as well as tips ... injury, and advice on when to seek medical attention. ... in the Youngstown Room; the evening session runs from 5:30 ...
Breaking Medicine News(10 mins):Health News:Quality of U.S. Diet Improves, Slightly 2Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 2Health News:Low-Carb Beats Low-Fat for Weight Loss, Heart Health: Study 3Health News:The 25th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 2Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 3Health News:North America Resectoscopes & Bronchoscopes Market (Revenue, Volume & Company Share) to 2020 Report Available at MarketOptimizer.org 4Health News:HMHP Offers ‘Health at Home’ Workshop 2
... health problems outside the lungs, researchers say , , WEDNESDAY, ... and long-term toxic effects on the heart and blood ... cause death, a new report says. , The ... issue of the Journal of the American College ...
... Physician Accuracy And ... Reduces Radiation Exposure for Patients, AUSTIN, Texas, Aug. ... Institute (TCAI) at St. David,s Medical Center became,the first ... -- an enhancement to the state-of-the art Hansen Robotic ...
... ("Assurant"),(NYSE: AIZ ), a premier provider of ... that Jane Meyer,has been appointed senior vice president, ... vice president, organizational development and,corporate communications effective immediately. ... and Mr. Walker will continue to report to ...
... Daily Dietary Supplements to Introduce Fashion Week ... Survival Kit at Verrier Runway Show, ... its,first-ever fashion partnership with breakout designer Ashleigh Verrier to,promote "Style ... healthy beauty during one of the most exciting and fast-paced,fashion ...
... the National Institutes of Health (NIH) have found a mechanism ... the development of autoimmune disease when turned off. The findings ... of autoimmunity and could also have implications for the development ... as cancer and HIV. The study paper appears online today ...
... strength, agility tied to brain damage, even in the ... -- Physical frailty among the elderly may be linked ... patients develop dementia, new research reveals. , The finding, ... the notion that motor impairment in the elderly is ...
Cached Medicine News:Health News:Air Pollution Can Damage Heart, Blood Vessels, Too 2Health News:Texas Cardiac Arrhythmia Institute at St. David's Medical Center First in the Nation to Use a New Generation of Medical Robots for Complex Electrophysiology Mapping Procedures 2Health News:Texas Cardiac Arrhythmia Institute at St. David's Medical Center First in the Nation to Use a New Generation of Medical Robots for Complex Electrophysiology Mapping Procedures 3Health News:Assurant Announces Two Executive Appointments 2Health News:VIACTIV(R) Partners With Rising Fashion Label Verrier to Launch 'Style and Strength for Life' Health Initiative at Fall Fashion Week 2008 2Health News:VIACTIV(R) Partners With Rising Fashion Label Verrier to Launch 'Style and Strength for Life' Health Initiative at Fall Fashion Week 2008 3Health News:NIH scientists find a novel mechanism that controls the development of autoimmunity 2Health News:Physical Frailty Could Predict Alzheimer's Disease 2Health News:Physical Frailty Could Predict Alzheimer's Disease 3
...
...
Tip is bent towards port for downward irrigation. 25G x 5/8in (.50 x 22mm)...
... Unique product designed for LASIK surgery and ... irrigate the corneal interface and/or stromal bed. ... flap and helps elevate the flap edge. ... (.40 x 22mm) Formed 9mm from end. ...
Medicine Products: